A. Treatment with PPI therapy is a required step before a formal diagnosis of EoE B. Response to a PPI indicates the presence of both EoE and GERD C. The level of response to a PPI correlates with severity of EoE D. A trial of a PPI is no longer required to make a diagnosis of EoE

A. It is characterized by an initial acute episode that spontaneously resolves B. It has a chronic course with changing symptomatology over time C. It is predominantly present in children and resolves during adolescence D. It has a variable disease course with some patients achieving remission in the absence of treatment

A. A period of endoscopic and histologic remission that lasts approximately 2 years B. A return of symptoms, including recurrent endoscopic and histologic signs, after approximately 6-8 months or less C. A recurrence of endoscopic and histologic signs that varies by type of steroid and route of administration D. A lack of effective of topical steroid therapy on endoscopic and histologic signs

A. To date, biologics have failed to demonstrate improvements in eosinophil counts and EoE-attributed symptoms B. An anti-IL-5 biologic is approved for treating EoE that failed to respond to topical steroid therapy C. Several biologic agents have demonstrated improvements in histologic and endoscopic responses and are being investigated in additional clinical trials D. Biologic agents have demonstrated efficacy on histologic and endoscopic endpoints in patients with PPI-nonresponsive EoE